Correction for “Engineering a protease-stable, oral single-domain antibody to inhibit IL-23 signaling,” by Naruhisa Ota, Christopher W. Davies, Jing Kang, Donghong Yan, Alexis Scherl, Anne Wong, Ryan Cook, Xun Tao, Debra Dunlap, Sha Klabunde, Priscilla Mantik, Vishnu Mohanan, WeiYu Lin, Jacqueline McBride, Shraddha Sadekar, Kelly M. Storek, Patrick Lupardus, Zhengmao Ye, Heidi Ackerly Wallweber, James R. Kiefer, Min Xu, Pamela Chan, Karthik Nagapudi, Tangsheng Yi, and James T. Koerber, which published May 28, 2025; 10.1073/pnas.2501635122 (Proc. Natl. Acad. Sci. U.S.A. 122, e2501635122).
The authors note that the terminal half-life estimates reported on pages 5 and 7 of the main text should appear in hours and not days. Specifically on page 5, left column, lines 1 to 3, “The volume distribution at steady state (Vss) was estimated as 396 mL/kg, and the terminal half-life was estimated as 2.37 d.” should appear as, “The volume distribution at steady state (Vss) was estimated as 396 mL/kg, and the terminal half-life was estimated as 2.37 h.” On page 7, right column, lines 2 to 4, “The volume distribution at steady state (Vss) was estimated as 249 mL/kg, and the terminal half-life was estimated as 4.08 d.” should appear as, “The volume distribution at steady state (Vss) was estimated as 249 mL/kg, and the terminal half-life was estimated as 4.08 h.” The online version has been corrected.